Adtaxi Honored at the Prestigious 2021 AdExchanger Awards
Oct 28 2021
Award Recognizes Best Use of Programmatic in a Marketing Campaign
DENVER — Besting a record number of entries, Adtaxi is honored to be the recipient of the Best Use of Programmatic in a Marketing Campaign at the 2021 AdExchanger Awards, the world’s premiere recognition program celebrating excellence in digital marketing and advertising. This award highlights Adtaxi’s programmatic strategy, helping its client cbdMD pivot during the pandemic from primarily brick and mortar retail to a focus on ecommerce.
“While ecommerce was a focus of our business, the mass lockdowns country-wide proved that it needed to become the driving force of revenue in 2020,” said John Wiesehan, cbdMD Chief Revenue Officer. “With that in mind, we challenged Adtaxi to bring their expertise in ecommerce to develop a new programmatic strategy to drive this growth. This resulted in a 2x increase in revenue generated from these efforts. We are honored that the AdExchanger Awards recognizes our joint accomplishments, and we know it would not be possible without Adtaxi’s strategic vision and execution.”
Adtaxi’s approach required a massive shift from cbdMD’s existing strategy within programmatic. Among those changes was a reimagining of cbdMD’s core audience targets. By re-evaluating the consumers buying CBD online, Adtaxi was able to segment and target several buckets of users with creatives designed specifically for their interests. These actions, and others, built a full funnel approach to targeting through a variety of channels such as display, native, and pre-roll video.
“cbdMD was forced to reassess its entire approach to digital marketing due to the startling effects of the pandemic,” said Jennifer Flanagan, Adtaxi Vice President of Marketing. “This pushed the team to rethink our programmatic strategy, allowing us to innovate in new and successful ways that we can use to drive growth for cbdMD and other clients in the future. We are thrilled to receive this honor for our partnership with cbdMD, and are proud of the successes we achieved.”
Full details on the award can be found HERE.
Founded in 2010 within MediaNews Group, Adtaxi made its mark in programmatic advertising before expanding into search, social, and connected TV. Over time, Adtaxi has refined and perfected its holistic performance-based strategy. Leveraging the power of people plus technology, Adtaxi’s innovative full-funnel methodology utilizes a variety of tools and processes. By using omnichannel optimizations across channels throughout the client lifecycle, they are able to maximize performance and deliver superior value for advertisers. Adtaxi functions as a true partner with its clients, acting as a single point of contact and support through multi-platform campaign cycles. Find Adtaxi on Twitter, LinkedIn and Facebook.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products. Our cbdMD brand currently includes over 130 SKUs of high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD bath salts, CBD sleep aids, CBD drink mixes and full spectrum CBD options. Our Paw CBD brand of pet products includes over 45 SKUs of veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and our CBD Botanicals brand of beauty and skincare products features 15 SKUs, including facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care. To learn more about cbdMD and their comprehensive line of U.S. grown, THC-free1 CBD oil products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook, or visit one of the 6,000 retail outlets that carry cbdMD products.
1 THC-free is defined as below the level of detection using validated scientific analytical methods
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 as filed with the Securities and Exchange Commission (the “SEC”) on December 22, 2020 and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.